Ever Supreme Bio Technology Co., Ltd
TWO: 6712.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Po-Ching Lee
- Employees
- 88
- Headquarters
- Taichung, Taiwan
- IPO year
- 2018
- Market cap
- NT$13.4B
- Website
- https://www.ever-supreme.com.tw
Loading 6712…
Loading profile data…Frequently asked questions about 6712
What does Ever Supreme Bio Technology Co., Ltd (6712.TWO) do?
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials f...
Where does 6712.TWO trade?
Ever Supreme Bio Technology Co., Ltd (6712.TWO) trades on the Taipei Exchange.
What sector is 6712.TWO in?
Ever Supreme Bio Technology Co., Ltd (6712.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ever Supreme Bio Technology Co., Ltd?
Po-Ching Lee is the chief executive officer of Ever Supreme Bio Technology Co., Ltd (6712.TWO).
Where is Ever Supreme Bio Technology Co., Ltd headquartered?
Ever Supreme Bio Technology Co., Ltd is headquartered in Taiwan.
Does 6712.TWO pay a dividend?
Yes — Ever Supreme Bio Technology Co., Ltd (6712.TWO) paid a trailing twelve-month dividend of TWD 3.50 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6712.TWO go public?
Ever Supreme Bio Technology Co., Ltd (6712.TWO) completed its initial public offering in 2018.